Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

Drug Safety Update, Issue 10

The Medicines and Healthcare products Regulatory Agency (MHRA) has published Drug Safety Update Issue 10 (PDF).

This issue includes the following drug safety advice articles:

  • Rimonabant (Acomplia): depression; psychiatric adverse reactions
  • Exenatide (Byetta): risk of acute pancreatitis

In addition, this issue contains a hot topic containing information about monitoring the safety of antiretroviral drugs. There is also a pointer to the Drug Analysis Print (DAP) area of the MHRA website. These DAP documents contain detailed listings of suspected adverse drug reactions reported to the MHRA through the Yellow Card scheme. Finally, there is a stop press section highlighting important safety issues that have arisen in the last month.

Action: Clinicians will find this publication to be a useful review of current issues in drug safety.

Share 'Drug Safety Update, Issue 10' on Email Share 'Drug Safety Update, Issue 10' on Delicious Share 'Drug Safety Update, Issue 10' on Digg Share 'Drug Safety Update, Issue 10' on Facebook Share 'Drug Safety Update, Issue 10' on Google+ Share 'Drug Safety Update, Issue 10' on reddit Share 'Drug Safety Update, Issue 10' on StumbleUpon Share 'Drug Safety Update, Issue 10' on Twitter

atomic-wealth

No Comments to “Drug Safety Update, Issue 10”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,431 spam comments.

atomic-wealth
fond-illness
summer